ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / KZIA
OGI (45) CATX (33) SPRB (34) BGM (37) ⌘ Pro Terminal →

Kazia Therapeutics Limited (KZIA) — RQD Stock Rating Cockpit

$8.02 -5.65% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $7.92

Kazia Therapeutics Limited (KZIA) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $132.2M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on KZIA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is KZIA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Kazia Therapeutics Limited (NASDAQ: KZIA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $8.02 (-5.65% 1D, market cap $132.2M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, KZIA ranks #310 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does KZIA compare to OGI and CATX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KZIA carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, OGI (Organigram Global Inc.) holds a D grade (45/100 RQD, P/E N/A, ROIC —, cap $131.6M) and CATX (Perspective Therapeutics Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $131.3M). Among the 5-stock peer group, KZIA leads on earnings multiple (N/A) while CATX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for KZIA?
▼

For Kazia Therapeutics Limited (KZIA), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #310 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $7.92 (-1.21%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.1% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510047
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- · Rk D+
Cash (12)Whales (5)SEC (13)Macro (8)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-5% Base Target
$18 Bull$8 Base$6 Bear
📬 FREE KZIA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KZIA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (47/100 Composite)
🔍 WHY KZIA SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (26% of score)

SEC XBRL Trailing 12 Months: 0.1% FCF Margin ($3.7M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
55
Grade C$8.04-2% Next Q
Q2 (-2Q)
52
Grade C-$7.88+3.7% Next Q
Q3 (-1Q)
50
Grade C-$8.17-1.8% Next Q
Current
47
Grade D$8.02-5.9% Hist 90D α
Trajectory: C (55) → D (47)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a KZIA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While KZIA currently carries a cautious 47/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($10.04) and Max Pain ($8.42) forces dealer call-delta covering toward $18.27.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $KZIA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “KZIA Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 47%NO 53%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
46.330 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
7 / 99-Pt Accounting
52-WEEK LASER RANGE25% OF RANGE
L: $5$8.02H: $17
1. Money & Cash Health● MIXED
Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: C-RQD 12 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 14 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D+RQD 21 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

Quant Analyst Panel Split (Battleground) on KZIA

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
NEUTRAL (60)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (37)

14/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like KZIA
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring KZIA)

  • ✓Walkthrough of KZIA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
KZIA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -37.54%📐 HORIZONTAL RANGE
2026-11-03O $8.72H $8.72L $8.02C $8.02VOL 230.4K
RES: $18.41SUP: $5.38SMA50: $10.04SMA200: $10.56
$17.92$14.86$11.79$8.73$5.67RES $18.41SUP $5.38$8.022026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KZIA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 KZIA Butterfly Map → + Track KZIA →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on KZIA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for KZIA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for KZIA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KZIA)

Health Care Rank #310 of 1015 ⚔️ OGI vs KZIA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (KZIA vs. OGI, CATX, SPRB, BGM)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Kazia Therapeutics Limited (KZIA) ranks #310 by composite RQD confidence (47/100, grade D) and #620 by equity capitalization ($132.2M). Within this direct 5-issuer industry benchmark cohort, KZIA leads on earnings valuation at N/A trailing P/E, while CATX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. KZIA currently leads its immediate peer cohort in composite quantitative strength at 47/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
KZIA ACTIVE
Kazia Therapeutics Limited
D 47/100 — — — -5.65% $132.2M Benchmark Subject
OGI
Organigram Global Inc.
D 45/100 — — — +3.43% $131.6M /ogi-vs-kzia →
CATX
Perspective Therapeutics Inc.
E 33/100 — — -35.0% -9.56% $131.3M /catx-vs-kzia →
SPRB
Spruce Biosciences Inc.
E 34/100 — — -35.0% -3.97% $133.3M /sprb-vs-kzia →
BGM
BGM Group Ltd. (Class A)
D- 37/100 — 16.6% — 0.00% $127.4M /bgm-vs-kzia →

2. KZIA Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Kazia Therapeutics Limited (KZIA) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $132.2M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. KZIA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KZIA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Kazia Therapeutics Limited (NASDAQ: KZIA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $8.02 (-5.65% 1D, market cap $132.2M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, KZIA ranks #310 in composite RQD confidence.

How does KZIA compare to OGI and CATX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KZIA carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, OGI (Organigram Global Inc.) holds a D grade (45/100 RQD, P/E N/A, ROIC —, cap $131.6M) and CATX (Perspective Therapeutics Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $131.3M). Among the 5-stock peer group, KZIA leads on earnings multiple (N/A) while CATX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for KZIA?

For Kazia Therapeutics Limited (KZIA), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #310 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is KZIA trading relative to its 50-day, 200-day, and 52-week technical levels?

KZIA last traded at $8.02 (-5.65% on volume of 156,040 shares), positioning the stock -20.12% below its 50-day simple moving average ($10.04) and -24.05% below its 200-day simple moving average ($10.56). Across its 52-week range of $4.86 to $17.40, KZIA sits at the 25.2% percentile with a 14-day RSI of 46.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($7.02 to $9.02).

Direct Sub-Reports: KZIA RQD Cockpit KZIA 12M Forecast KZIA Earnings & Move KZIA Dividends & DRIP KZIA Insiders & 13F KZIA Whale Options KZIA Profit Sankey KZIA News & Why
ROARABLE RATING BRIEF • RQD 47/100 (D) ✓ SEC XBRL & RQD VERIFIED

KZIA — Kazia Therapeutics Limited: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

Kazia Therapeutics Limited (KZIA) earns a live Roarable RQD composite score of 47/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $8.02 (-5.65% 1D, market capitalization $132.2M).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Kazia Therapeutics Limited (KZIA) is a NASDAQ-listed issuer in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry. Its market capitalization is $0.1B per the company profile.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 47/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 5/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $4.86 – $17.40 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The one ripple-relevant item is the large lock-up share count noted in the news feed; the scale of that overhang relative to the $0.1B market capitalization is a second-order consideration for float and supply of shares.

  • Key Question #1: Can KZIA sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $17.40 52-week high?
  • Key Question #3: How sensitive is KZIA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

KZIA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Kazia Therapeutics Limited (KZIA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to KZIA Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

KZIA Bull vs. Bear Conversation Board — What's Your Call at $8.02?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON KZIA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on KZIA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $10.20 (+20.0%)
📌 Pinned Debate

Balance-sheet forensics are the strongest RQD input (Altman Z 2.5, Piotroski F 6/9, Debt/Equity 0.5) and a TradingView headline cites a

Long KZIA at $8.50 targeting $10.20. Balance-sheet forensics are the strongest RQD input (Altman Z 2.5, Piotroski F 6/9, Debt/Equity 0.5) and a TradingView headline cites a 12-month target raised to $31.83.. Institutional whale score is 5/20 and the risk/reward vs. the $4.86 52-week low is skewed heavily in favor of bulls.

RetailWhale_TX 🐂 BULL

Both sides have a point here — KZIA's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $7.22 (-15.1%)
Spot @ $8.50

ROIC and FCF yield are both 0% and insider conviction scores only 9 / 20, while 5,713,449,734 shares face a lock-up expiry on 28-OCT-20

Sitting on the sidelines or leaning short KZIA above $8.50. ROIC and FCF yield are both 0% and insider conviction scores only 9 / 20, while 5,713,449,734 shares face a lock-up expiry on 28-OCT-2026.. Until Fundamental Cash Engine (12/20) and FCF yield (0.0%) inflect higher, upside is capped near $17.40.

LIVE TAPE